EDETEK to Present at the 44th Annual J.P. Morgan Healthcare Conference
Accelerating Clinical Development through AI-Powered R&D Cloud Ecosystem and Solutions
The presentation will outline EDETEK's strategic roadmap and innovations that are transforming clinical development, including the R&D Cloud Ecosystem, therapeutic accelerators such as ONCO+, BioStat.AI, Agentic AI, and other AI solutions and services.
"EDETEK is committed to driving innovation that accelerates clinical development and improves quality," said
"We are building solutions that transform clinical operations and development to create sustainable value for patients, sponsors, CROs and investors," added Dr.
Why It Matters
The global clinical trials market is projected to exceed
Webcast and Replay
EDETEK will consider webcast and replay requests made via its website for a limited time following the event. To schedule a meeting during JPM, visit www.edetek.com.
About EDETEK
Founded in 2009, EDETEK provides AI-powered platforms and clinical services to pharmaceutical, biotechnology and medical device companies worldwide. The company serves more than one hundred and twenty biopharma clients across four continents with a focus on innovation, interoperability and quality in clinical development. EDETEK's platforms and services have supported over 50 successful regulatory filings.
Disclaimer:
This release may include statements regarding future plans, strategies and anticipated benefits of EDETEK's platforms. These statements are based on current expectations and are subject to change without notice.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edetek-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302657952.html
SOURCE EDETEK, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sophia Space and SLI Set Terms for $300 Million Asset Financing for 10-Satellite High-Performance Edge Computing Constellation
- Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
- Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share